CANC.US Tema Oncology ETF
- Total assets
- 217M
- Expense ratio
- 0.78%
- Dividend yield
- 0.05%
- 1-year return
- +33.50%
- Holdings
- 56
- Since
- 2023
Fund data as reported by the issuer, updated Nov 13, 2026. Total assets are in the fund's base currency.
What does CANC.US invest in?
- Mostly US stocks (85.5%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (83.9%)
- Top 3 holdings: 16.8% of the fund
Asset allocation
- US stocks 85.5%
- Non-US stocks 18.3%
- Cash 0.6%
Top holdings
- Genmab AS 5.83%
- Revolution Medicines Inc 5.71%
- Eli Lilly and Company 5.24%
- Merck & Company Inc 4.73%
- Cogent Biosciences Inc 4.53%
Tema Oncology ETF performance
Sharpe ratio 1.14- This year
- +23.25%
- 1 year
- +33.50%
- 3 years
- +27.19%
- 5 years
- -
Volatility 19.7% over 1 year and 19.2% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
CANC.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About Tema Oncology ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
Full fund profileTema Oncology ETF top holdings
45.0% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Genmab AS GMAB.US | Healthcare | United States | 5.83% |
| Revolution Medicines Inc RVMD.US | Healthcare | United States | 5.71% |
| Eli Lilly and Company LLY.US | Healthcare | United States | 5.24% |
| Merck & Company Inc MRK.US | Healthcare | United States | 4.73% |
| Cogent Biosciences Inc UMRX.US | Healthcare | United States | 4.53% |
| BeiGene Ltd BGNE.US | Healthcare | United States | 4.14% |
| Novartis AG NOVN.SW | Healthcare | Switzerland | 3.98% |
| Exelixis Inc EXEL.US | Healthcare | United States | 3.82% |
| AbbVie Inc ABBV.US | Healthcare | United States | 3.76% |
| Roche Holding Ltd ADR RHHBY.US | Healthcare | United States | 3.22% |
The 10 largest of 56 holdings.
CANC.US sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
CANC.US regional exposure
- North America83.9%
- Europe Developed13.6%
- United Kingdom2.4%
- Asia Emerging2.0%
Share of the stocks in the fund.
Company size
Average market cap 28.1B- Mega cap14.3%
- Big cap21.7%
- Medium cap17.1%
- Small cap20.9%
- Micro cap20.6%
Tema Oncology ETF fund profile
- Fund name
- Tema Oncology ETF
- Ticker
- CANC.US
- Exchange
- USA Stocks
- Issuer
- Tema ETFs
- Index tracked
- -
- Category
- Healthcare Equity
- Inception date
- Aug 14, 2023
- Trading currency
- USD
- Expense ratio
- 0.78%
About Tema Oncology ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.